01 Integration of Artificial Intelligence in Digital Pathology The growing volume of whole-slide images and demand for faster, consistent tissue assessment are encouraging the integration of artificial intelligence into digital pathology workflows. The FDA qualified the AI-based AIM-NASH tool in 2025 to help pathologists assess liver biopsy features in MASH clinical trials, showing how AI can support standardized histologic evaluation while keeping pathologists responsible for final interpretation. This transition can improve quantitative image assessment and support more efficient diagnostic and clinical research workflows.
02 Adoption of Whole-Slide Imaging for Routine Diagnosis The need for accessible, high-resolution digital examination of tissue samples is supporting the adoption of whole-slide imaging for clinical pathology workflows. FDA classifications recognize whole-slide imaging systems and digital pathology viewing software as technologies that allow pathologists to review scanned pathology slides for primary diagnosis, while recent research highlights their use in clinical diagnostics and remote collaboration. This shift can reduce dependence on conventional microscope-based workflows and support digital consultation, image sharing, and integration with AI-based analysis.
01 Remote Consultation and Centralized Pathology Services Drive Market The need for specialist pathology expertise across geographically separated healthcare facilities creates requirements for digital systems that support remote case review. The FDA recognizes digital pathology as a clinical technology that can support remote access to pathology images and diagnostic information, while its guidance addresses digital pathology systems used for primary diagnosis. For example, a regional hospital can share a complex biopsy case with a specialist at a larger medical center for a second opinion without transferring the physical glass slide. This consultation requirement supports the use of digital pathology platforms and encourages providers to supply secure image-sharing and remote review solutions.The need for consistent pathology expertise across multiple healthcare facilities creates a preference for centralized laboratory workflows that consolidate specialized resources and case review. NCI's pathology shared resources provide centralized pathology services and expertise for cancer research, including tissue processing, histology, and pathology consultation. For example, a hospital network can route selected pathology cases from smaller facilities to a central laboratory for specialist review and reporting through digital systems. This operating model supports investment in digital pathology infrastructure and creates requirements for image management, data storage, and secure case-sharing systems.
01 Reimbursement and Image Quality Challenges Restrain Market Expansion Limited reimbursement for digital pathology services can reduce the financial incentive for laboratories and healthcare providers to invest in scanners, software, storage, and related infrastructure. The absence of clear or adequate payment policies can make it more difficult for providers to recover the costs of digital implementation and ongoing operation. This financial barrier can delay adoption and slow the growth of the digital pathology market.Scanner and image quality variability can arise from differences in resolution, color reproduction, focusing accuracy, image processing, and tissue preparation across digital pathology systems. FDA identifies technical performance areas such as color reproducibility, spatial resolution, and focusing accuracy as important considerations for whole-slide imaging systems. These variations can increase validation requirements and reduce confidence in consistent diagnostic performance, slowing the adoption of digital pathology technologies.
01 Digital Pathology Training and Hospital Partnerships Offers Growth Opportunities Pathologists, laboratory technicians, medical schools, and digital pathology providers can use specialized training resources to build skills in digital workflows and slide interpretation. Leica biosystems provides webinars and educational resources covering digital pathology adoption and implementation, creating revenue through training programs, professional education, and related support services.Digital pathology companies and hospitals can collaborate on system deployment, workflow integration, training, and long-term support. Philips partnered with saint-joseph and marie-lannelongue hospitals to integrate digital pathology into their enterprise imaging workflow, with the hospitals processing more than 150,000 histology slides annually, creating revenue through scanners, software, implementation, and support services.
01 System Integration and Image Data Management Hinders Growth Digital pathology platforms must integrate with laboratory information systems, electronic health records, image-management systems, and existing laboratory workflows. Proprietary data formats and interoperability challenges between whole-slide imaging components can increase customization and implementation requirements. These integration requirements can increase costs and slow deployment across healthcare organizations.Whole-slide images generate large digital files that require substantial storage, backup, retrieval, and archiving infrastructure. The large size of digital pathology images can increase IT requirements as laboratories expand their digital slide libraries. These requirements can increase infrastructure expenditure and make large-scale deployment more difficult for laboratories with limited digital capabilities.
June 2026 Roche expanded its digital pathology portfolio with enhanced AI-powered image analysis and workflow solutions. The company focused on improving pathology efficiency, biomarker assessment, and personalized medicine applications through integrated digital platforms.
March 2026 Philips expanded its digital pathology solutions with advanced image management and AI-enabled diagnostic technologies. The developments support remote pathology workflows, collaboration, and improved diagnostic accuracy in healthcare systems.
January 2026 Danaher expanded its digital pathology capabilities through advancements across its pathology technology businesses, including AI-based image analysis and laboratory workflow solutions. The initiatives support precision diagnostics and research applications.
October 2025 Leica Biosystems expanded its digital pathology platform with enhanced scanning, image analysis, and workflow automation technologies. The company focused on improving laboratory efficiency and supporting AI-assisted diagnostic decision-making.